MarketPulse

GLP-1 agonists

3 articles
Investing.comInvesting.com··Nathan Reiff

Lilly's Double-Beat Widens GLP-1 Gap as Foundayo Pill Transforms Market

Eli Lilly beats Q1 earnings, raises $2B guidance, and wins FDA approval for Foundayo, the first unrestricted oral GLP-1, widening gap over Novo Nordisk.
LLYNVOFDA approvalweight loss medications
The Motley FoolThe Motley Fool··James Brumley

Viking Therapeutics Stock Could Double as GLP-1 Rival Advances Toward FDA Approval

Wall Street projects 170% upside for Viking Therapeutics' obesity drug candidate VK2735, citing superior weight loss and tolerability versus Novo Nordisk and Eli Lilly rivals.
LLYNVOVKTXFDA approvalPhase 3 trials
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Eli Lilly's Weight-Loss Dominance Faces Pipeline Challengers, But Lead Remains Secure

Eli Lilly dominates weight-loss pharmaceuticals with 45% 2025 revenue growth, maintaining market lead despite competitor advances due to years-long regulatory timelines.
LLYNVORHHBYREGNclinical trialsweight loss drugs